Novel Tools for Diagnosis and Monitoring of AML
In recent years, major advances in the understanding of acute myeloid leukemia (AML) pathogenesis, together with technological progress, have led us into a new era in the diagnosis and follow-up of patients with AML. A combination of immunophenotyping, cytogenetic and molecular studies are required...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/30/6/395 |
| _version_ | 1797595341861683200 |
|---|---|
| author | Francesca Guijarro Marta Garrote Neus Villamor Dolors Colomer Jordi Esteve Mónica López-Guerra |
| author_facet | Francesca Guijarro Marta Garrote Neus Villamor Dolors Colomer Jordi Esteve Mónica López-Guerra |
| author_sort | Francesca Guijarro |
| collection | DOAJ |
| description | In recent years, major advances in the understanding of acute myeloid leukemia (AML) pathogenesis, together with technological progress, have led us into a new era in the diagnosis and follow-up of patients with AML. A combination of immunophenotyping, cytogenetic and molecular studies are required for AML diagnosis, including the use of next-generation sequencing (NGS) gene panels to screen all genetic alterations with diagnostic, prognostic and/or therapeutic value. Regarding AML monitoring, multiparametric flow cytometry and quantitative PCR/RT-PCR are currently the most implemented methodologies for measurable residual disease (MRD) evaluation. Given the limitations of these techniques, there is an urgent need to incorporate new tools for MRD monitoring, such as NGS and digital PCR. This review aims to provide an overview of the different technologies used for AML diagnosis and MRD monitoring and to highlight the limitations and challenges of current versus emerging tools. |
| first_indexed | 2024-03-11T02:35:59Z |
| format | Article |
| id | doaj.art-9d0f82e0ca4d402d82dbf88e4e70ed4d |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-11T02:35:59Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-9d0f82e0ca4d402d82dbf88e4e70ed4d2023-11-18T09:57:35ZengMDPI AGCurrent Oncology1198-00521718-77292023-05-013065201521310.3390/curroncol30060395Novel Tools for Diagnosis and Monitoring of AMLFrancesca Guijarro0Marta Garrote1Neus Villamor2Dolors Colomer3Jordi Esteve4Mónica López-Guerra5Hematopathology Section, Pathology Department, Hospital Clinic Barcelona, 08036 Barcelona, SpainHematopathology Section, Pathology Department, Hospital Clinic Barcelona, 08036 Barcelona, SpainHematopathology Section, Pathology Department, Hospital Clinic Barcelona, 08036 Barcelona, SpainHematopathology Section, Pathology Department, Hospital Clinic Barcelona, 08036 Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), 08036 Barcelona, SpainHematopathology Section, Pathology Department, Hospital Clinic Barcelona, 08036 Barcelona, SpainIn recent years, major advances in the understanding of acute myeloid leukemia (AML) pathogenesis, together with technological progress, have led us into a new era in the diagnosis and follow-up of patients with AML. A combination of immunophenotyping, cytogenetic and molecular studies are required for AML diagnosis, including the use of next-generation sequencing (NGS) gene panels to screen all genetic alterations with diagnostic, prognostic and/or therapeutic value. Regarding AML monitoring, multiparametric flow cytometry and quantitative PCR/RT-PCR are currently the most implemented methodologies for measurable residual disease (MRD) evaluation. Given the limitations of these techniques, there is an urgent need to incorporate new tools for MRD monitoring, such as NGS and digital PCR. This review aims to provide an overview of the different technologies used for AML diagnosis and MRD monitoring and to highlight the limitations and challenges of current versus emerging tools.https://www.mdpi.com/1718-7729/30/6/395AMLdiagnosisMRD monitoringflow cytometryNGSdigital PCR |
| spellingShingle | Francesca Guijarro Marta Garrote Neus Villamor Dolors Colomer Jordi Esteve Mónica López-Guerra Novel Tools for Diagnosis and Monitoring of AML Current Oncology AML diagnosis MRD monitoring flow cytometry NGS digital PCR |
| title | Novel Tools for Diagnosis and Monitoring of AML |
| title_full | Novel Tools for Diagnosis and Monitoring of AML |
| title_fullStr | Novel Tools for Diagnosis and Monitoring of AML |
| title_full_unstemmed | Novel Tools for Diagnosis and Monitoring of AML |
| title_short | Novel Tools for Diagnosis and Monitoring of AML |
| title_sort | novel tools for diagnosis and monitoring of aml |
| topic | AML diagnosis MRD monitoring flow cytometry NGS digital PCR |
| url | https://www.mdpi.com/1718-7729/30/6/395 |
| work_keys_str_mv | AT francescaguijarro noveltoolsfordiagnosisandmonitoringofaml AT martagarrote noveltoolsfordiagnosisandmonitoringofaml AT neusvillamor noveltoolsfordiagnosisandmonitoringofaml AT dolorscolomer noveltoolsfordiagnosisandmonitoringofaml AT jordiesteve noveltoolsfordiagnosisandmonitoringofaml AT monicalopezguerra noveltoolsfordiagnosisandmonitoringofaml |